Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Le..., Sonic AI
Home
/
Outcomes Rocket
/
Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Le...
Outcomes Rocket
Notify me
•
Jun 17, 2026
•
24:03
Interview
Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Le...
From
Outcomes Rocket
Steve Mather
(Global Practice Lead for Strategy and Insights, Lumanity, guest)
Get the full transcript next time Outcomes Rocket releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
A convergence of policies, including the US Inflation Reduction Act (IRA) and Europe's Joint Clinical Assessment (JCA), is fundamentally rewriting the pharmaceutical commercialization playbook by compressing revenue horizons and increasing evidence demands.
The traditional sequential model of drug development is now obsolete; value must be designed into an asset from the earliest stages, as commercial excellence at launch cannot recover value lost due to poor initial strategy.
Companies must shift to a "policy-adjusted" approach, making critical decisions on indication sequencing, clinical trial design, and pricing architecture much earlier in the development cycle.
This new reality requires early, integrated, cross-functional teams that incorporate local market insights to navigate complex evidence requirements and optimize an asset's global potential.
Continue your research
Keep pulling the thread on Steve Mather.
Policy Convergence and its Multiplier Effect
The Primacy of Early-Stage Strategy
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed Jun 24, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini